Shares of NextCure Inc (NASDAQ:NXTC) have received an average broker rating score of 1.30 (Strong Buy) from the five brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. NextCure’s rating score has declined by 11.1% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Analysts have set a one year consensus price target of $72.25 for the company and are anticipating that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also assigned NextCure an industry rank of 58 out of 255 based on the ratings given to related companies.
Several analysts have weighed in on the company. Zacks Investment Research lowered NextCure from a “buy” rating to a “hold” rating in a report on Tuesday, November 12th. Morgan Stanley lifted their price target on NextCure from $33.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $87.00 price target (down previously from $95.00) on shares of NextCure in a research note on Wednesday, November 20th. Needham & Company LLC initiated coverage on shares of NextCure in a research report on Thursday. They issued a “buy” rating and a $72.00 price objective on the stock. Finally, BTIG Research started coverage on shares of NextCure in a research note on Tuesday, November 26th. They issued a “buy” rating and a $61.00 price objective on the stock.
NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $1.58 million during the quarter, compared to analysts’ expectations of $1.50 million. As a group, equities analysts anticipate that NextCure will post -2.19 EPS for the current fiscal year.
In other NextCure news, major shareholder Sofinnova Venture Partners Ix, acquired 150,000 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was acquired at an average cost of $36.75 per share, with a total value of $5,512,500.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
A number of hedge funds have recently bought and sold shares of NXTC. Victory Capital Management Inc. acquired a new stake in NextCure during the 2nd quarter valued at $48,000. Strs Ohio lifted its position in shares of NextCure by 625.0% in the third quarter. Strs Ohio now owns 5,800 shares of the company’s stock valued at $178,000 after acquiring an additional 5,000 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of NextCure in the second quarter valued at $96,000. Morgan Stanley purchased a new stake in shares of NextCure in the second quarter valued at $101,000. Finally, Northern Trust Corp acquired a new stake in shares of NextCure during the second quarter valued at $337,000. 49.62% of the stock is currently owned by hedge funds and other institutional investors.
NextCure Company Profile
There is no company description available for NextCure Inc
See Also: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.